List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatitis D - Overview
Hepatitis D - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis D - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis D - Companies Involved in Therapeutics Development
CN Bio Innovations Ltd
Eiger BioPharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Globeimmune Inc
Hepion Pharmaceuticals Inc
Merck & Co Inc
MYR GmbH
PharmaEssentia Corp
Replicor Inc
Rodos BioTarget GmbH
SomaGenics Inc
Hepatitis D - Drug Profiles
Antisense RNAi Oligonucleotide for Hepatitis D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bulevirtide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRV-431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GI-18000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lonafarnib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon lambda-1a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBT-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REP-2139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REP-2165 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Hepatitis D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Hepatitis B and Hepatitis D Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vanitaracin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis D - Dormant Projects
Hepatitis D - Product Development Milestones
Featured News & Press Releases
Nov 12, 2019: Eiger announces Peginterferon Lambda - Lonafarnib combination interim results in Hepatitis Delta Virus (HDV) infection from phase 2 LIFT study during late-breaker oral presentation at AASLD 2019
Nov 01, 2019: MYR Pharmaceuticals announces multiple presentations at the AASLD Meeting 2019 in Boston
Oct 21, 2019: Eiger announces Peginterferon Lambda combination therapy for treatment of chronic hepatitis delta virus (HDV) infection to be featured in a late-breaking oral presentation at AASLD 2019
Aug 20, 2019: Eiger announces FDA breakthrough therapy designation for Peginterferon Lambda for treatment of hepatitis delta virus infection
Jul 29, 2019: Replicor announces publication of new study examining HBsAg evolution during REP 2139
Jun 10, 2019: Replicor presents final REP 401 data demonstrating persistent functional cure of HBV
May 17, 2019: Eiger BioPharmaceuticals announces transition of Chief Operating Officer and Executive Medical Officer
Apr 11, 2019: Eiger Announces 36% durable virologic response at 24 weeks post-treatment with peginterferon lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
Apr 04, 2019: MYR Pharmaceuticals announces presentation of final results of the MYR203 study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna
Apr 01, 2019: Replicor to present latest data on the beneficial impact of transaminase flares in achieving HBV functional cure at the 2019 EASL ILC meeting
Mar 26, 2019: Eiger BioPharmaceuticals to Participate in Conferences in April 2019
Mar 26, 2019: Eiger BioPharmaceuticals to participate in conferences
Mar 13, 2019: Eiger late-breaker oral presentation of peginterferon lambda Phase 2 LIMT study at The International Liver Congress 2019
Mar 05, 2019: MYR Pharma announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the first-in-class entry inhibitor for treatment of chronic hepatitis d infections
Feb 06, 2019: Eiger Biopharmaceuticals announces patent protection for Lonafarnib boosted with Ritonavir for treatment of hepatitis delta virus infection in Europe and Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hepatitis D, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hepatitis D - Pipeline by CN Bio Innovations Ltd, H1 2020
Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, H1 2020
Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Hepatitis D - Pipeline by Globeimmune Inc, H1 2020
Hepatitis D - Pipeline by Hepion Pharmaceuticals Inc, H1 2020
Hepatitis D - Pipeline by Merck & Co Inc, H1 2020
Hepatitis D - Pipeline by MYR GmbH, H1 2020
Hepatitis D - Pipeline by PharmaEssentia Corp, H1 2020
Hepatitis D - Pipeline by Replicor Inc, H1 2020
Hepatitis D - Pipeline by Rodos BioTarget GmbH, H1 2020
Hepatitis D - Pipeline by SomaGenics Inc, H1 2020
Hepatitis D - Dormant Projects, H1 2020

List of Figures
Number of Products under Development for Hepatitis D, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
• CN Bio Innovations Ltd
• Eiger BioPharmaceuticals Inc
• F. Hoffmann-La Roche Ltd
• Globeimmune Inc
• Hepion Pharmaceuticals Inc
• Merck & Co Inc
• MYR GmbH
• PharmaEssentia Corp
• Replicor Inc
• Rodos BioTarget GmbH
• SomaGenics Inc